<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2177</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕЧЕНИЕ ПАЦИЕНТОВ С СЕРДЕЧНО-СОСУДИСТЫМИ ЗАБОЛЕВАНИЯМИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MANAGEMENT OF CARDIOVASCULAR PATIENTS</subject></subj-group></article-categories><title-group><article-title>Миокардиальные цитопротекторы оказывают антиапоптотический эффект на эндотелиоциты сосудистой стенки</article-title><trans-title-group xml:lang="en"><trans-title>Myocardial cytoprotectors demonstrate anti-apoptotic effect on vascular endotheliocytes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Инжутова</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Inzhutova</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>старший научный сотрудник</p></bio><email xlink:type="simple">alyonainzhutova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ молекулярной медицины и патобиохимии Красноярского государственного медицинского университета им. проф. В.Ф. Войно-Ясенецкого. Красноярск</institution></aff><aff xml:lang="en"><institution>Research Institute of Molecular Medicine and Pathobiochemistry, V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University. Krasnoyarsk</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>01</day><month>01</month><year>1970</year></pub-date><volume>9</volume><issue>8</issue><fpage>29</fpage><lpage>32</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Инжутова А.И., 1970</copyright-statement><copyright-year>1970</copyright-year><copyright-holder xml:lang="ru">Инжутова А.И.</copyright-holder><copyright-holder xml:lang="en">Inzhutova A.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2177">https://cardiovascular.elpub.ru/jour/article/view/2177</self-uri><abstract><sec><title>Цель</title><p>Цель. Определить влияние миокардиальных цитопротекторов на содержание эндотелиоцитов в состоянии апоптоза и мембран-высвобожденных микрочастиц эндотелиального генеза в периферической крови пациентов с сердечно-сосудистыми заболеваниями (ССЗ). Материал и методы. В исследовании с информированного согласия приняли участие пациенты с ССЗ — гипертонической болезнью (ГБ) без ишемической болезни сердца (ИБС) и с ГБ на фоне ИБС. В качестве группы (гр.) контроля (ГК) была выделена гр. пациентов с рабочим диагнозом нейроциркуляторная дистония (НЦД). У всех пациентов проводили забор периферической венозной крови до назначения и на фоне 3-недельного приема триметазидина МВ. В последующем методом центрифугирования выделяли эндотелиальные клетки и мембран-высвобожденные микрочастицы. Результаты. Прием триметазидина МВ вызвал статистически значимый регресс содержания слущенных эндотелиоцитов и мембран-высвобожденных микрочастиц в основных гр. (ОГ) и ГК (p&lt;0,05). Заключение. Триметазидин МВ может быть использован как патогенетическая терапия, направленная на коррекцию гомеостаза сосудистой стенки у больных ССЗ, и в качестве средства профилактики прогрессирования эндотелиальной дисфункции у больных с рабочим диагнозом НЦД.</p></sec><sec><title> </title><p> </p></sec></abstract><trans-abstract xml:lang="en"><p>Aim. To evaluate the effects of myocardial cytoprotectors on the levels of apoptotic endotheliocytes and membranederived microparticles of endothelial origin in peripheral blood of the patients with cardiovascular disease (CVD). Material and methods. The study included CVD patients with arterial hypertension (AH) and coronary heart disease (CHD) or AH only, all of whom gave informed consent. The control group (CG) included patients with neuro-circulatory dystonia (NCD). In all participants, peripheral blood samples were taken at baseline and after 3 weeks of trimetazidine MR therapy, to assess the levels of endotheliocytes and membrane-derived microparticles. Results. Trimetazidine MR treatment resulted in significantly reduced levels of apoptotic endotheliocytes and membrane-derived microparticles in the two main groups and the CG (p&lt;0,05). Conclusion. Trimetazidine MR could be used as pathogenetic therapy, correcting vascular wall homeostasis in CVD patients, and also as prevention of endothelial dysfunction progression in NCD patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эндотелиальная дисфункция</kwd><kwd>апоптоз</kwd><kwd>мембран-высвобожденные микрочастицы</kwd><kwd>триметазидин МВ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelial dysfunction</kwd><kwd>apoptosis</kwd><kwd>membrane-derived microparticles</kwd><kwd>trimetazidine MR</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pober JS, Min W, Bradley JR. Mechanisms of endothelial dysfunction, injury, and death. Pathology: Mechanisms of Disease 2009; 4: 71-95.</mixed-citation><mixed-citation xml:lang="en">Pober JS, Min W, Bradley JR. Mechanisms of endothelial dysfunction, injury, and death. Pathology: Mechanisms of Disease 2009; 4: 71-95.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi N, DeLano FA, Schmid-Schönbein GW. Oxidative stress promotes endothelial cell apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscl Thromb Vasc Biol 2005; 25: 2114-21.</mixed-citation><mixed-citation xml:lang="en">Kobayashi N, DeLano FA, Schmid-Schönbein GW. Oxidative stress promotes endothelial cell apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscl Thromb Vasc Biol 2005; 25: 2114-21.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Preston RA, Jy W, Preston JRA. Effects of severe hypertension on endothelial and platelet Microparticles. Hypertension 2003; 41: 211-3.</mixed-citation><mixed-citation xml:lang="en">Preston RA, Jy W, Preston JRA. Effects of severe hypertension on endothelial and platelet Microparticles. Hypertension 2003; 41: 211-3.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Azevedo LCP, Pedro MA, Laurindo FRM. Circulating microparticles as therapeutic targets in cardiovascular. Diseases Recent Patents on Cardiovascular Drug Discovery 2007; 2: 41-51.</mixed-citation><mixed-citation xml:lang="en">Azevedo LCP, Pedro MA, Laurindo FRM. Circulating microparticles as therapeutic targets in cardiovascular. Diseases Recent Patents on Cardiovascular Drug Discovery 2007; 2: 41-51.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Deregibus MC, Cantaluppi V, Calogero R, et al. Endothelial progenitor cell-derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. BLOOD 2007; 7(110): 2440-8.</mixed-citation><mixed-citation xml:lang="en">Deregibus MC, Cantaluppi V, Calogero R, et al. Endothelial progenitor cell-derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. BLOOD 2007; 7(110): 2440-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Iwata Y, Kuzuya F, Hayakawa M, et al. Circulating endothelial cells fail to induce cerebral infarction in rabbits. Stroke 1986; 3(17): 506-9.</mixed-citation><mixed-citation xml:lang="en">Iwata Y, Kuzuya F, Hayakawa M, et al. Circulating endothelial cells fail to induce cerebral infarction in rabbits. Stroke 1986; 3(17): 506-9.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
